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Background: Pulmonary hypertension (PHT) is a recently recognized complication
of chronic kidney disease. In this study, we investigated the association between
PHT, peripheral vascular calciﬁcations (VCs), and major cardiovascular events.
Methods: In this retrospective study, we included 172 end-stage renal disease
(ESRD) patients undergoing dialysis [hemodialysis (HD)¼84, peritoneal dia-
lysis¼88]. PHT was deﬁned as an estimated pulmonary artery systolic pressure
437 mmHg using echocardiography. The Simple Vascular Calciﬁcation Score (SVCS)
was measured using plain radiographic ﬁlms of the hands and pelvis.
Results: The prevalence of PHT was signiﬁcantly higher in HD patients (51.2% vs.
22.7%). Dialysis patients with PHT had a signiﬁcantly higher prevalence of severe
VCs (SVCSZ3). In multivariate analysis, the presence of severe VCs [odds ratio (OR),
2.68], mitral valve disease (OR, 7.79), HD (OR, 3.35), and larger left atrial diameter
(OR, 11.39) were independent risk factors for PHT. In addition to the presence of
anemia, severe VCs, or older age, the presence of PHT was an independent predictor
of major cardiovascular events in ESRD patients.
Conclusion: The prevalence of PHT was higher in HD patients and was associated
with higher rates of major cardiovascular events. Severe VCs are thought to be an
independent risk factor for predicting PHT in ESRD patients. Therefore, in dialysis
patients with PHT, careful attention should be paid to the presence of VCs and the
occurrence of major cardiovascular events.
Copyright & 2015. The Korean Society of Nephrology. Published by Elsevier. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Emerging evidence suggests that pulmonary hypertension
(PHT), a recently recognized complication of end-stage renal
disease (ESRD), is closely associated with cardiac, pulmonary,15. The Korean Society of Nep
.org/licenses/by-nc-nd/4.0/).
al Medicine, Korea
nam Hospital, 73 Incho-
o).and systemic diseases and also with increased mortality [1]. The
prevalence of PHT is known to range from 18.8% to 68.8% in
hemodialysis (HD) patients and from 0% to 42% in peritoneal
dialysis (PD) patients [2]. The possible causes of PHT in dialysis
patients are classiﬁed into three categories: (1) increased cardiac
output caused by an arteriovenous ﬁstula, anemia, or hypervole-
mia; (2) increased pulmonary vascular resistance caused by
uremic endothelial dysfunction, pulmonary embolism, pulmonary
artery calciﬁcations, or other comorbid diseases including chronic
obstructive pulmonary disease or connective tissue disease; and
(3) elevated pulmonary capillary wedge pressure caused byhrology. Published by Elsevier. This is an open access article under the
Kim et al / PHT in dialysis patients 29systolic and diastolic heart failure or mitral valve disease [3]. In a
previous study on dogs, high parathyroid hormone levels pro-
voked pulmonary artery calciﬁcations, and this resulted in
decreased pulmonary vascular compliance [4]. Although this result
indicated that extraosseous calciﬁcations might be a risk factor for
PHT, results in human studies about the association between PHT
and pulmonary artery calciﬁcation or parathyroid hormone levels
have been conﬂicting [5–9]. Medial artery calciﬁcation is a
common complication in patients with chronic kidney disease
(CKD) contributing to increased cardiovascular mortality, and
multiple factors including abnormal calcium phosphate metabo-
lism, uremia, oxidative stress, and inﬂammation are known to be
important in vascular calciﬁcation (VC) development. In this study,
we examined the association between PHT, peripheral VCs, and
major cardiovascular events in dialysis patients.Methods
Study population
In this retrospective study, we included 172 ESRD patients
undergoing dialysis (HD¼84, PD¼88) who had been enrolled in
previous cross-sectional studies performed in March 2009 [10,11].
In the previous studies, 198 stable dialysis patients (HD¼105,
PD¼93) who had been followed in the dialysis center of Korea
University Anam Hospital with over 6-mo duration of dialysis
were enrolled. Among 198 patients, 26 without echocardiographic
data were excluded from this study. Baseline characteristics,
including sex, age, body weight, height, dialysis duration, causes
of ESRD, and history of hypertension, diabetes, ischemic heart
disease, and chronic obstructive pulmonary disease were
recorded. The mean values of serum albumin, low-density lipo-
protein (LDL) cholesterol, alkaline phosphatase, calcium, phos-
phate, hemoglobin, and C-reactive protein (CRP) that had been
measured every month for 18 months were used. The data
collection on baseline characteristics, laboratory tests, and echo-
cardiographic ﬁndings was based on the enrollment date of the
previous studies. The electronic medical records of enrolled
patients from March 2009 to December 2013 were reviewed to
check for the development of major cardiovascular events includ-
ing acute myocardial infarction and stroke. For acute myocardial
infarction, we included non-ST elevation and ST elevation myo-
cardial infarction. We deﬁned stroke as an abrupt onset of focal
neurological deﬁcit with intracranial infarction or hemorrhage on
brain imaging studies, during the follow-up period. This study was
approved by the Institutional Review Board of Korea University,
Anam Hospital.
Echocardiography
Standard two-dimensional, M-mode, Doppler echocardiogra-
phy was performed for all patients. We used the modiﬁed
Bernoulli equation to calculate pulmonary artery systolic pressure
(PASP) as follows: PASP¼4 (tricuspid systolic jet)2þ10 mmHg
(estimated arterial pressure). PHT was deﬁned as an estimated
PASP437 mmHg. Left ventricular (LV) mass was calculated
with the following formula: LV mass (g)¼0.8 {1.04
[(LVIDdþPWTdþSWTd)3 – (LVIDd)3]}þ0.6, where LVIDd is the
left ventricle internal diameter, diastole; PWTd is the posterior
wall thickness, diastole; and SWTd is the septum wall thickness,
diastole. This was indexed for body surface area to yield the LV
mass index [12]. LV systolic dysfunction was deﬁned as LVfractional shorteningr25%. Mitral valve disease was deﬁned as
mitral valve stenosis or regurgitation with more than moderate
degree. Aortic valve disease was also deﬁned as stenosis or
regurgitation of aortic valve with more than moderate degree.
Simple Vascular Calciﬁcation Score and parathyroid hormone
level
The Simple Vascular Calciﬁcation Score (SVCS) was mea-
sured using plain radiographic ﬁlms of both hands and pelvis.
The pelvic radiographic ﬁlm was arbitrarily divided into four
sections by two imaginary lines (a horizontal line over the
upper limit of both femoral heads and a median vertical line
over the vertebral column). For each hand, the ﬁlm was
divided by a horizontal line over the upper limit of the
metacarpal bones. Only the linear calciﬁcations in the iliac,
femoral, radial, and digital arteries were counted. The presence
of linear calciﬁcations in each section was counted as a score of
1, and the absence of calciﬁcations was counted as a score of 0;
the SVCS was the sum of all sections, ranging from 0 to 8.
Adragao et al [13] found that an SVCSZ3 was an independent
predictor of cardiovascular mortality and cardiovascular
events. According to this result, we deﬁned severe VCs as an
SVCSZ3. We also deﬁned an intact parathyroid hormone
levelo150 pg/mL as the low parathyroid hormone group and
an intact parathyroid hormone level4300 pg/mL as the high
parathyroid hormone group based on the Kidney Disease
Outcomes Quality Initiative guidelines [14].
Statistical analysis
Statistical analyses were performed using SPSS, version 20.0
(SPSS, Inc., Chicago, IL, USA). Data are presented as the means
7standard deviation or median (interquartile range), according
to distribution. Continuous variables were analyzed using the
Student t test for normally distributed data or the Mann–Whitney
test for non-normally distributed data. The Pearson χ2 test was
used to analyze nominal data. In multivariate analysis, a binary
logistic regression model was used. The major cardiovascular
events-free survivals were determined based on survival curves
using the Kaplan–Meier method and log-rank test. The effect of
prognostic factors on major cardiovascular events was examined
using the Cox proportional regression model. All parameters used
in the cross-sectional study were evaluated using a univariate Cox
proportional hazard model. Those covariates with Po0.20 in the
univariate model were considered for the multivariate Cox
regression analysis. Patients were censored at kidney transplanta-
tion (n¼28), last follow-up (n¼45), and death (n¼21). A P
valueo0.05 was considered statistically signiﬁcant.Results
Baseline characteristics according to dialysis modality
The mean age of the patients was 56.3713.2 years.
Seventy-four patients (43.0%) had a history of diabetes, and
152 patients (88.4%) had hypertension. The most common
cause of ESRD was diabetes mellitus, followed by hyperten-
sion, glomerulonephritis, and polycystic kidney disease. There
was no statistically signiﬁcant difference in the causes of ESRD
or comorbidities according to dialysis modality. Of the 172
dialysis patients, 63 (36.6%) had PHT, and the median dialysis
Kidney Res Clin Pract 34 (2015) 28–3430duration before enrollment was 35.0 (18.5–64.0) months. The
prevalence of PHT was signiﬁcantly higher in HD patients
(51.2% vs. 22.7%, Po0.001). ESRD patients undergoing PD had
lower serum albumin and CRP levels. Serum LDL cholesterol,
high-density lipoprotein (HDL) cholesterol, triglyceride, alka-
line phosphatase, and intact parathyroid hormone levels were
signiﬁcantly higher in PD patients. However, there were no
statistically signiﬁcant differences in echocardiographic ﬁnd-
ings such as LV mass index, left atrial diameter, LV segmental
abnormalities, LV systolic dysfunction, and the prevalence of
mitral valve disease between HD and PD patients (Table 1).Risk factors that predict the presence of PHT
Univariate analysis of the various factors predicting the
presence of PHT is presented in Table 2. Dialysis patients with
PHT had a signiﬁcantly higher prevalence of severe VCs
(SVCSZ3), LV systolic dysfunction, and mitral valve disease.
They also had higher LV mass indices and larger left atrial
diameters. However, the difference in the causes of ESRD or
comorbidities between the PHT and no PHT groups was not
statistically signiﬁcant. In multivariate analysis, we used a binary
logistic regression model and included all variables with a PTable 1. Baseline characteristics according to the dialysis modality
All (n¼172)
Age, y 56.3713.2
Sex (male) 86 (50.0%)
Body weight (kg) 59.9710.2
Height (m) 1.6070.08
BMI (kg/m2) 22.8 (21.0–25.1)
Dialysis duration (mo) 35.0 (18.5–64.0)
Comorbidities
Diabetes mellitus 74 (43.0%)
Hypertension 152 (88.4%)
Ischemic heart disease 15 (8.7%)
COPD 7 (4.1%)
Causes of renal failure
Glomerulonephritis 25 (14.5%)
Hypertension 52 (30.2%)
Diabetes mellitus 69 (40.1%)
Polycystic kidney disease 5 (2.9%)
Others 21 (12.2%)
Intact parathyroid hormone (pg/mL) 191 (109–391)
Intact parathyroid hormone group (150–300)
Low 49 (28.5%)
Intermediate 65 (37.8%)
High 58 (33.7%)
SVCSZ3 48 (27.9%)
Albumin (g/dL) 3.8770.42
LDL cholesterol (mg/dL) 90.3720.2
HDL cholesterol (mg/dL) 40.6 (35.0–47.5)
Triglyceride (mg/dL) 127.2 (91.9–160.3)
ALP (IU/L) 67.8 (57.6–89.6)
Ca–P (mg2/dL2) 44.7 (37.8–51.0)
Hemoglobin (g/dL) 10.3 (9.9–10.7)
CRP (mg/L) 2.25 (1.16–4.81)
Pulmonary hypertension 63 (36.6%)
Echo ﬁndings
LV mass index 129.4740.4
Left atrial diameter (cm/m2) 2.4670.48
LV segmental abnormality 11 (6.4%)
LV systolic dysfunction (LVFSo25%) 16 (9.3%)
MV disease 18 (10.5%)
AV disease 10 (5.8%)
All values are expressed as mean7standard deviation, number of patients
ALP, alkaline phosphatase; AV, aortic valve; BMI, body mass index; COPD, ch
HD, hemodialysis; HDL, high-density lipoprotein; LDL, low-density lipopro
mitral valve; PD, peritoneal dialysis; SVCS, simple vascular calciﬁcation scorvalueo0.2 in the univariate analysis (Table 3). Severe VCs [odds
ratio (OR), 2.68, P¼0.013], mitral valve disease (OR, 7.79,
P¼0.005), HD (OR, 3.35, P¼0.003), and larger left atrial diameter
(OR, 11.39, P¼0.005) were independent risk factors for PHT.
Risk factors that predict the severe VCs
Patients with severe VCs were older and had a signiﬁcantly
higher prevalence of diabetes and PHT. They also had signiﬁ-
cantly lower intact parathyroid hormone and HDL cholesterol
levels (Table 4). To identify the risk factors that independently
predict severe VCs, we applied a binary logistic regression
model and included all variables with a P valueo0.2 in the
univariate analysis (Table 5). The presence of diabetes mellitus
(OR, 14.23, Po0.001), PHT (OR, 2.66, P¼0.030), low parathyr-
oid hormone level (OR, 12.63, Po0.001), and also high para-
thyroid hormone level (OR, 5.25, P¼0.017) were independent
risk factors for severe VCs.
Major cardiovascular event-free survival
By December 2013, the median follow-up period was 46.9
months. The major cardiovascular events-free survival rates atHD (n¼84) PD (n¼88) P
58.3714.3 54.8712.3 0.093
44 (52.4%) 42 (47.7%) 0.647
59.3710.6 60.479.7 0.486
1.6070.08 1.5970.08 0.598
22.7 (21.0–24.2) 23.1 (20.9–25.5) 0.261
35.0 (21.0–63.0) 36.5 (15.0–67.0) 0.980
34 (40.5%) 40 (45.5%) 0.540
75 (89.3%) 77 (87.5%) 0.814
9 (10.7%) 6 (6.8%) 0.425
5 (6.0%) 2 (2.3%) 0.269
14 (16.7%) 11 (12.5%) 0.667
28 (33.3%) 24 (24.3%)
30 (35.7%) 39 (44.3%)
3 (3.6%) 2 (2.3%)
9 (10.7%) 12 (13.6%)
176 (86–312) 225 (134–440) 0.019
24 (28.6%) 25 (28.4%) 0.031
39 (46.4%) 26 (29.5%)
21 (25.0%) 37 (42.0%)
26 (31.0%) 22 (25.0%) 0.401
4.0270.37 3.7370.43 <0.001
85.3720.3 95.1719.0 0.001
40.0 (32.1–45.5) 41.1 (35.4–48.7) 0.027
110.3 (76–144) 144.5 (111–175) <0.001
65.3 (52.5–84.0) 73.4 (60.4–100.8) 0.029
42.8 (37.2–49.4) 45.8 (38.4–51.5) 0.236
10.2 (9.9–10.6) 10.4 (9.8–10.8) 0.519
4.54 (1.51–8.29) 1.79 (1.08–2.51) <0.001
43 (51.2%) 20 (22.7%) <0.001
133.3741.5 125.6739.2 0.214
2.5070.55 2.4270.42 0.295
6 (7.1%) 5 (5.7%) 0.763
6 (7.1%) 10 (11.4%) 0.434
12 (14.3%) 6 (6.8%) 0.137
5 (6.0%) 5 (5.7%) 1.000
(%), or median (conﬁdence interval 25–75%).
ronic obstructive lung disease; CRP, C-reactive protein; Hb, hemoglobin;
tein; LV, left ventricle; LVFS, left ventricular fractional shortening; MV,
e.
Table 2. Characteristics according to the pulmonary hypertension
No PHT (n¼109) PHT (n¼63) P
Age, y 55.0713.9 59.0712.2 0.059
Sex (male) 54 (49.5%) 32 (50.8%) 1.000
Body weight (kg) 59.9710.5 59.979.6 0.974
Height (m) 1.5970.08 1.6070.08 0.634
BMI (kg/m2) 22.9 (20.8–25.5) 22.5 (21.3–24.3) 0.833
Hemodialysis 41 (37.6%) 43 (68.3%) <0.001
Dialysis duration (mo) 34.0 (18.0–65.0) 40.0 (19.5–63.0) 0.927
Comorbidities
Diabetes mellitus 43 (39.4%) 31 (49.2%) 0.263
Hypertension 93 (85.3%) 59 (93.7%) 0.139
Ischemic heart disease 7 (6.4%) 8 (12.7%) 0.172
COPD 3 (2.8%) 4 (6.3%) 0.261
Causes of renal failure
Glomerulonephritis 16 (14.7%) 9 (14.3%) 0.709
Hypertension 34 (31.2%) 18 (28.6%)
Diabetes mellitus 40 (36.7%) 29 (46.0%)
Polycystic kidney disease 4 (3.7%) 1 (1.6%)
Others 15 (13.8%) 6 (9.5%)
Intact parathyroid hormone (pg/mL) 198 (124–398) 174 (77–422) 0.534
Intact parathyroid hormone group (150–300)
Low 38 (34.9%) 27 (42.9%) 0.352
Intermediate 35 (32.1%) 14 (22.2%)
High 36 (33.0%) 22 (34.9%)
SVCSZ3 23 (21.1%) 25 (39.7%) 0.013
Albumin (g/dL) 3.98 (3.65–4.17) 3.97 (3.64–4.12) 0.648
LDL cholesterol (mg/dL) 90.7718.4 89.7723.1 0.752
HDL cholesterol (mg/dL) 43.0712.0 40.6710.8 0.192
Triglyceride (mg/dL) 145.8776.5 132.9781.1 0.298
ALP (IU/L) 67.8 (59.5–91.5) 68.1 (53.7–85.9) 0.468
Ca–P (mg2/dL2) 45.6 (37.8–50.5) 43.7 (38.0–51.8) 0.695
Hb (g/dL) 10.3 (9.9–10.7) 10.3 (9.9–10.6) 0.598
CRP (mg/L) 2.17 (1.08–4.16) 2.49 (1.42–7.57) 0.072
Echo ﬁndings
LV mass index 119.2737.7 146.8739.2 <0.001
Left atrial diameter (cm/m2) 2.3370.48 2.6970.40 <0.001
LV segmental abnormality 7 (6.4%) 4 (6.3%) 1.000
LV systolic dysfunction (LVFSo25%) 6 (5.5%) 10 (15.9%) 0.031
MV disease 3 (2.8%) 15 (23.8%) <0.001
AV disease 6 (5.5%) 4 (6.3%) 1.000
All values are expressed as mean7standard deviation, number of patients (%), or median (conﬁdence interval 25–75%).
ALP, alkaline phosphatase; AV, aortic valve; BMI, body mass index; COPD, chronic obstructive lung disease; CRP, C-reactive protein; Hb, hemoglobin;
HDL, high-density lipoprotein; LDL, low-density lipoprotein; LV, left ventricle; LVFS, left ventricular fractional shortening; MV, mitral valve; PHT,
pulmonary hypertension; SVCS, simple vascular calciﬁcation score.
Table 3. Multivariate logistic regression analysis of risk factors
associated with pulmonary hypertension (backward method)
OR 95% CI P
Hemodialysis 3.35 1.59–7.03 0.003
Hypertension 3.42 0.77–15.22 0.106
SVCSZ3 2.68 1.22–5.86 0.013
Left atrial diameter (cm/m2) 11.39 10.40–12.47 0.005
MV disease 7.79 1.88–32.20 0.005
Excluded variables: age, ischemic heart disease, high-density lipoprotein
cholesterol, C-reactive protein, left ventricular mass index, and left
ventricular systolic dysfunction.
CI, conﬁdence interval; MV, mitral valve; OR, odds ratio; SVCS, simple
vascular calciﬁcation score.
Kim et al / PHT in dialysis patients 311, 2, and 4 years in dialysis patients with PHT were signiﬁ-
cantly lower than those in patients without PHT (94.9% vs.
98.0%, 92.7% vs. 90.9%, and 79.6% vs. 91.7%, log-rank test
P¼0.026; Fig. 1). All variables in the cross-sectional study
were evaluated using the univariate Cox proportional regres-
sion model, and Table 6 shows all variables found to be
associated with major cardiovascular events at the Po0.20level. In a multivariate Cox proportional regression analysis,
age [hazard ratio (HR) 1.05, P¼0.044], the presence of severe
VCs (HR, 4.09, P¼0.010), PHT (HR, 3.11, P¼0.035), and hemo-
globin level (HR, 0.43, P¼0.022) were signiﬁcant predictors for
major cardiovascular events.Discussion
In this study, we observed the following: (1) HD patients
had a higher prevalence of PHT than PD patients; (2) severe
peripheral VCs (SVCSZ3) were independent risk factors for
PHT; and (3) in addition to the old age, presence of anemia, or
severe VCs, the presence of PHT was an independent predictor
of major cardiovascular events in dialysis patents.
PHT is deﬁned as a mean pulmonary artery pressure
425 mmHg using right heart catheterization. However, clin-
ical utility of right heart catheterization has been hampered by
the invasive nature of this procedure. Therefore, we used
echocardiography as a noninvasive method to diagnose PHT
by the modiﬁed Bernoulli equation [5–9,15]. In previous
studies with CKD patients, estimated PASP ranging from 25
to 45 mmHg was used as the cutoff value of PHT [2]. In the
2009 European Society of Cardiology (ESC) guideline,
Table 4. Characteristics according to the severe vascular calciﬁcations
SVCS<2 (n¼124) SVCSZ3 (n¼48) P
Age, y 54.7713.8 61.0711.3 0.003
Sex (male) 59 (47.6%) 27 (56.3%) 0.395
Body weight (kg) 59.4710.8 61.078.1 0.301
Height (m) 1.6070.08 1.6070.08 0.923
BMI (kg/m2) 22.5 (20.8–25.2) 223.1 (22.0–25.0) 0.125
Hemodialysis 58 (46.8%) 26 (54.2%) 0.401
Dialysis duration (mo) 34.5 (19.0–67.0) 40.5 (16.0–62.5) 0.782
Comorbidities
Diabetes mellitus 34 (27.4%) 40 (83.3%) 0.000
Hypertension 108 (87.1%) 44 (91.7%) 0.596
Ischemic heart disease 9 (7.3%) 6 (12.5%) 0.365
COPD 3 (2.4%) 4 (8.3%) 0.096
Intact parathyroid hormone (pg/mL) 237.2 (147.9–419.7) 123.4 (71.1–293.0) 0.001
Intact parathyroid hormone group (150–300)
Low 33 (26.6%) 32 (66.7%) 0.000
Intermediate 45 (36.3%) 4 (8.3%)
High 46 (37.1%) 12 (25.0%)
Pulmonary hypertension 38 (30.6%) 25 (52.1%) 0.013
Albumin (g/dL) 3.9 (3.6–4.1) 3.8 (3.4–4.1) 0.070
LDL cholesterol (mg/dL) 91.6719.2 86.9722.4 0.173
HDL cholesterol (mg/dL) 41.0 (35.3–48.8) 37.0 (29.7–44.5) 0.023
Triglyceride (mg/dL) 128.5 (98.5–159.2) 117.3 (83.6–182.3) 0.724
ALP (IU/L) 67.1 (58.1–88.5) 71.6 (58.2–95.0) 0.352
Ca–P (mg2/dL2) 44.4 (38.6–51.8) 45.4 (36.5–50.1) 0.424
Hb (g/dL) 10.3 (9.9–10.7) 10.2 (9.8–10.7) 0.586
CRP (mg/L) 2.15 (1.09–4.18) 2.80 (1.25–5.75) 0.087
All values are expressed as mean7standard deviation, number of patients (%), or median (conﬁdence interval
25–75%).
ALP, alkaline phosphatase; BMI, body mass index; COPD, chronic obstructive lung disease; CRP, C-reactive protein;
Hb, hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SVCS, simple vascular calciﬁcation
score.
Table 5. Multivariate logistic regression analysis of risk factors
associated with severe vascular calciﬁcations (backward method)
OR 95% CI P
Diabetes mellitus 14.23 5.50–36.82 o0.001
Intact parathyroid hormone
group (150–300)
Intermediate – – –
Low 12.63 3.53–45.14 o0.001
High 5.25 1.34–20.49 0.017
Pulmonary hypertension 2.66 1.09–6.44 0.030
Excluded variables: age, chronic obstructive lung disease, albumin, low-
density lipoprotein cholesterol, high-density lipoprotein cholesterol,
and C-reactive protein.
CI, conﬁdence interval; OR, odds ratio.
Figure 1. Major cardiovascular event-free survival in end-stage renal
disease patients with (dotted line) and without (solid line) pulmon-
ary hypertension (PHT).
Kidney Res Clin Pract 34 (2015) 28–3432estimated PASP of 37–50 mmHg was deﬁned as “PHT possi-
ble,” and estimated PASP450 as “PHT likely.” In this study, we
deﬁned PHT as an estimated PASPZ37 mmHg based on the
ESC guideline [16]. We ﬁrst observed that a substantial
number of dialysis patients had PHT (36.6%) and also that
the prevalence of PHT in HD patients was signiﬁcantly higher
than that in PD patients (51.2% vs. 22.7%). This ﬁnding is in
accordance with several previous studies demonstrating that
the prevalence of PHT in HD patients (18.8–68.8%) was
signiﬁcantly higher than that in PD patients (0–42%) [2].
PHT can be classiﬁed into ﬁve categories according to the
World Health Organization classiﬁcation system: (1) pulmon-
ary arterial hypertension (Group 1); (2) PHT caused by left
heart disease (Group 2); (3) PHT caused by chronic lung
disease and/or hypoxia (Group 3); (4) chronic thromboembolicPHT (Group 4); and (5) PHT caused by unclear multifactorial
mechanisms (Group 5) [1]. PHT occurring in CKD patients can
Table 6. Univariate and multivariate Cox regression models for major cardiovascular events
Univariate Multivariate (backward)
HR (95% CI) P HR (95% CI) P
Age 1.04 (1.00–1.09) 0.021 1.05 (1.00–1.11) 0.044
BMI 1.12 (0.99–1.27) 0.056
Diabetes mellitus 1.95 (0.75–5.05) 0.166
Intact parathyroid hormone group (150–300)
Intermediate 1.00 – 1.00 –
Low 1.79 (0.32–9.82) 0.498 0.41 (0.06–2.85) 0.417
High 5.82 (1.30–26.04) 0.021 4.55 (0.98–20.98) 0.052
SVCSZ3 2.35 (0.92–5.96) 0.071 4.09 (1.40–11.92) 0.010
Albumin 0.38 (0.13–1.08) 0.070
ALP (per 10 IU/L) 1.05 (1.00–1.10) 0.041
Hb 0.63 (0.34–1.14) 0.131 0.43 (0.21–0.88) 0.022
LV mass index 1.01 (1.00–1.02) 0.044
Pulmonary hypertension 2.80 (1.08–7.23) 0.033 3.11 (1.08–8.98) 0.035
ALP, alkaline phosphatase; BMI, body mass index; CI, conﬁdence interval; Hb, hemoglobin; HR, hazard ratio; LV, left ventricle; SVCS, simple vascular
calciﬁcation score.
Kim et al / PHT in dialysis patients 33be classiﬁed into Groups 1–4 according to the underlying
causes of PHT; however, a considerable number of patients
(30–50%) are classiﬁed into Group 5, that is, PHT caused by
unknown or multifactorial mechanisms. The possible causes of
PHT in ESRD patients are thought to be increased cardiac
output caused by the presence of an arteriovenous ﬁstula,
anemia, and/or hypervolemia. In addition, increased pulmon-
ary vascular resistance caused by uremic endothelial dysfunc-
tion, pulmonary embolism, pulmonary artery calciﬁcation, and
increased pulmonary capillary wedge pressure related to heart
failure or mitral valve disease might also play an important
role [3]. A signiﬁcantly higher prevalence of PHT in HD
patients compared with PD patients suggests that among
these factors, increased LV ﬁlling pressure caused by the
presence of an arteriovenous ﬁstula, a unique feature of HD,
is likely to be important because other factors such as anemia,
prevalence of LV systolic dysfunction, left atrial diameter, or
mitral valve disease did not differ according to dialysis mod-
ality in our study.
In the dialysis patients, VC can be measured by cardiac
computed tomography (CT), plain X-ray, ultrasound, echocar-
diography, or pulse wave velocity [17]. Although CT-based
imaging has an advantage in quantitative measurement or in
sequential monitoring of the progression of calciﬁcation,
difﬁculty in distinguishing intima from medial calciﬁcation,
higher cost, or higher amount of radiation exposure are
thought to be its limitations. On the contrary, plain X-ray has
merits of lower cost, less radiation exposure, and ability to
distinguish medial calciﬁcation, but quantitative measurement
is impossible. Although ultrasound or pulse wave velocity can
also be used for assessing VC, operator dependency or impos-
sibility of direct measurement of calciﬁcation is a major
limitation, respectively.
In this study, we used plain X-ray to measure SVCS and
observed that severe VC (SVCSZ3) is an independent pre-
dictor of PHT. VC, a major complication of CKD, theoretically
could involve pulmonary vascular beds and subsequently
increase PHT risk. Although no studies have demonstrated
the association between peripheral and pulmonary VCs, CKD
patients with a milieu of accelerated extraosseous calciﬁcation
may have increased VC not only in the peripheral artery but
also in the coronary or pulmonary arteries [10,18]. We pre-
viously showed that peripheral VC can predict coronary
calciﬁcation in PD patients [10]. Although we did not assesspulmonary artery calciﬁcation, we observed the signiﬁcantly
higher prevalence of severe peripheral VC in patients with PHT
and also that the presence of severe VCs is an independent risk
factor for PHT, suggesting that peripheral VC is closely asso-
ciated with PHT development.
A previous study on dogs reported that high parathyroid
hormone levels provoked pulmonary VCs and subsequently
reduced pulmonary vascular compliance [4]. Accordingly,
several clinical trials also reported that high parathyroid
hormone levels can be a risk factor for PHT. However, other
clinical trials reported a lack of association between parathyr-
oid hormone levels and PHT [6–9]. Although there were strong
relationships between intact parathyroid hormone levels and
severe VCs in our study, we observed no association between
intact parathyroid hormone levels and PHT. However, further
studies are needed to verify the exact relationship between
parathyroid hormone and PHT development.
Cardiac dysfunction is a common cause of PHT, and as
expected, we observed that the prevalence of mitral valve
disease was 10.5% in dialysis patients, being an independent
risk factor for PHT in our study. In addition, left atrial diameter
but not LV systolic dysfunction or LV mass index was strongly
associated with PHT, suggesting that chronic volume overload
is a risk factor for PHT regardless of myocardial dysfunction in
dialysis patients.
Although it is well-known that PHT is closely associated
with volume overload or cardiac diseases, data showing the
impact of PHT on cardiovascular mortality or events have been
insufﬁcient [7,19–21]. Only one study has reported that PHT
can predict cardiovascular mortality and events in HD patients
[22]. In this study, we deﬁned major cardiovascular events as
acute myocardial infarction or stroke and showed that dialysis
patients with PHT had decreased major cardiovascular events-
free survivals. In addition, the presence of severe VCs, older
age, and decreased hemoglobin levels were also independent
predictors for the development of major cardiovascular events
in multivariate analysis. Although the precise mechanisms
leading to increased cardiovascular events in dialysis patients
with PHT are unclear, there is a possibility that increased VC, a
well-known risk factor for cardiovascular disease, might be
important in PHT development. Therefore, in addition to
routine screening of PHT in CKD patients, efforts to maintain
proper ﬂuid volume status or to reduce left atrial size by
surgical reduction of oversized arteriovenous ﬁstula could be
Kidney Res Clin Pract 34 (2015) 28–3434considered when clinically indicated [21,23]. In terms of VC,
early initiation of hyperphosphatemia management or use of
noncalcium containing phosphate binder is needed in CKD
patients [24].
Despite several meaningful ﬁndings, there are some limita-
tions to our study. First, this was a retrospective cohort study
that enrolled only a limited number of patients with relatively
short follow-up period in a single center. Second, the diagnosis
of PHT might be inaccurate, because PHT was deﬁned by the
indirect method of echocardiography rather than by the direct
measure of pulmonary arterial systolic pressure with right
heart catheterization. Third, there is a possibility that incon-
sistency in timing of echocardiography in terms of HD session
might affect the results. However, in our analysis, there was no
statistically signiﬁcant difference in the prevalence of PHT
according to timing of echocardiography (before or after HD,
data not shown). In conclusion, the prevalence of PHT in
dialysis patients is substantially high, and the presence of
PHT is an independent risk factor for major cardiovascular
events. PHT is also closely associated with peripheral VC,
suggesting that the mechanisms underlying the development
of CKD–mineral bone disorder might be partially responsible
for PHT. Careful attention should be paid to the relationship
between PHT, peripheral VCs, and cardiovascular disease in the
care of ESRD patients, and further studies that could clarify the
underlying mechanism are needed.Conﬂict of interest
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